Moderna (NASDAQ: MRNA) shares closed trading on Friday, June 26, with a strong 12% gain. Over the past six months, the stock price of the American biotech giant has surged 125.51% from lows near $46 recorded in early June. This impressive rise is not a coincidence but the result of a confluence of several key factors.

FDA Removed the Main Risk

About a week and a half ago, on June 18, the FDA's Vaccines and Related Biological Products Advisory Committee unanimously (9 out of 9 votes) approved a positive assessment of mFLUSIVA (mRNA-1010), a seasonal influenza vaccine based on mRNA technology for people over 50. Unanimous decisions in biotech are rare, and this event sharply reduced regulatory uncertainty ahead of the key decision date for the application on August 5.

If the FDA approves mFLUSIVA, it will be the first seasonal influenza vaccine in the U.S. based on an mRNA platform. The market interpreted this as a signal that Moderna can replicate the success of its COVID-19 vaccine in a new segment. However, as I note in my analysis, actual sales are still far off: analysts do not expect significant revenue from this drug before 2027.

Wall Street Remains Cautious

Despite the rally, sentiment on Wall Street remains mixed. Piper Sandler raised its price target for MRNA to $77, while Jefferies analysts raised theirs to $53, maintaining a "hold" rating. The median analyst forecast is just $43.45—significantly below current quotes. This suggests that the market is pricing in future expectations rather than current performance.

Insider transactions also lean toward selling: the last 75 trades were sell-offs. This is a classic signal: those inside the company are locking in profits after such a surge.

Not Just Vaccines: New Strategy and Oncology

Moderna has reorganized its business, carving out three divisions: vaccines, oncology, and rare diseases. This news lifted quotes by about 6.3%. At the Science Day event on June 25, the company presented an expanded development portfolio, including programs for in vivo CAR-T and T-cell engagers for oncology and autoimmune diseases.

Additionally, plans to invest in production in Germany, including sites that BioNTech intends to close, led to an 8–12% rise in MRNA shares over several trading sessions. Market participants viewed this move as a long-term bet on increasing capacity ahead of a wave of new launches in 2027–2028.

Expert Commentary: Moderna's rally is a classic example of the market revaluing a company based on future expectations rather than current financial performance. The breakthrough in the influenza vaccine and diversification into oncology are strong catalysts, but the current price already builds in high expectations. Investors should remember: the FDA's unanimous decision is just the beginning of the journey, and actual sales and profits are still years away. I recommend maintaining caution and not chasing emotional growth without a clear understanding of the risks.